Get the Stockscreener App
0.871
2.34%
-0.0209
After Hours:
.89
0.019
+2.18%
Oncolytics Biotech Inc stock is traded at $0.871, with a volume of 281.00K.
It is down -2.34% in the last 24 hours and down -9.18% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.
See More
Previous Close:
$0.8919
Open:
$0.88
24h Volume:
281.00K
Relative Volume:
1.57
Market Cap:
$66.94M
Revenue:
-
Net Income/Loss:
$-20.59M
P/E Ratio:
-2.6016
EPS:
-0.3348
Net Cash Flow:
$-17.99M
1W Performance:
-4.22%
1M Performance:
-9.18%
6M Performance:
-17.83%
1Y Performance:
-60.05%
1-Day Range:
$0.87
$0.903
1-Week Range:
$0.87
$0.93
52-Week Range:
$0.85
$2.22
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
Oncolytics Biotech's SWOT analysis: pelareorep progress lifts stock outlook - Investing.com India
Oncolytics Biotech's SWOT analysis: pela drug potential drives stock outlook By Investing.com - Investing.com UK
Oncolytics Biotech (TSE:ONC) Reaches New 12-Month Low at $1.20 - Defense World
Promising Progress in Oncology as Cancer Deaths Decline and Research Grows - Baystreet.ca
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase - Benzinga
Global study predicts sharp rise in cancer rates among men by 2050 - Benefits and Pensions Monitor
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs - ForexTV.com
Investors Watch Key Players in Oncology as Cancer Cases Set to Skyrocket - Baystreet.ca
Oncolytics Biotech (TSE:ONC) Given New C$3.50 Price Target at Raymond James - Defense World
Oncolytics Biotech (NASDAQ:ONCY) Receives Buy Rating from HC Wainwright - Defense World
Oncolytics Biotech (TSE:ONC) Price Target Raised to C$3.50 at Raymond James - MarketBeat
Global Cancer Rates Surge as Biotech Innovators Work on New Therapies - cnhinews.com
Abbvie Inc (ABBV-N) QuotePress Release - The Globe and Mail
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs - GlobeNewswire
Recent Breakthroughs in Cancer Research Could Impact These Key Companies - Baystreet.ca
Oncolytics Biotech (NASDAQ:ONCY) Earns Buy Rating from HC Wainwright - MarketBeat
Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players - Benzinga
Oncolytics Biotech reports positive results from breast cancer study | 2024-09-19 | Investing News - Stockhouse Publishing
Oncolytics Biotech reports promising breast cancer study results - Investing.com India
Oncolytics Biotech reports promising breast cancer study results By Investing.com - Investing.com Australia
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study - PR Newswire
Oncolytics Biotech (NASDAQ:ONCY) Stock Price Down 0.7% - Defense World
Oncolytics Biotech (NASDAQ:ONCY) Trading Down 0.7% - MarketBeat
Oncolytics Biotech Engages Investors at Key Conferences - TipRanks
Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September - IT News Online
Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September - PR Newswire
Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September - Canada NewsWire
Oncolytic Virus Therapy Market to See Booming Growth 2024-2031 | - openPR
Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September - Barchart
Oncolytic Virus Cancer Therapy Market - Future Market Insights
Oncolytics Biotech Inc. Forecasted to Earn FY2024 Earnings of ($0.29) Per Share (NASDAQ:ONCY) - MarketBeat
HC Wainwright Weighs in on Oncolytics Biotech Inc.'s FY2024 Earnings (TSE:ONC) - MarketBeat
HC Wainwright Analysts Decrease Earnings Estimates for Oncolytics Biotech Inc. (NASDAQ:ONCY) - Defense World
Oncolytics Biotech (NASDAQ:ONCY) Receives "Buy" Rating from HC Wainwright - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Earns “Buy” Rating from HC Wainwright - Defense World
Thinking about buying stock in Oncolytics Biotech, Nikola Corp, Joby Aviation, Ideanomics, or Better Therapeutics? - GuruFocus.com
Oncolytics Biotech® to Host Conference Call to Discuss Second Qu - GuruFocus.com
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer - Longview News-Journal
Oncolytics Biotech’s Pelareorep Shows Promise in Metastatic Breast Cancer Treatment - Vancity Buzz
Stock Surge: Oncolytics Biotech, Inc. (ONCY) Closes at 0.91, Marking a -4.06 Increase/Decrease - The Dwinnex
Extending Survival: Oncolytics Biotech's Pelareorep Shows Promise In Fighting Metastatic Breast Cancer - Nasdaq
Biotech Innovations Poised to Transform Pancreatic Cancer Treatment and Patient Outcomes - Baystreet.ca
Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates - Barchart
Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates - Quantisnow
Advancements In Cancer Therapeutics: What To Expect From The Upcoming 2024 Oncology Conference - MENAFN.COM
Biotech Innovations Drive Pancreatic Cancer Treatment: Market Expected To Reach $7.4 Billion By 2032 - MENAFN.COM
Virtu Financial LLC Acquires New Stake in Oncolytics Biotech Inc. (NASDAQ:ONCY) - Defense World
Oncolytic Virus Therapy Market Expected to Expand at a Steady - openPR
ONCY:UN - BNN Bloomberg
Oncolytics Biotech Announces Equity Distribution Deal - TipRanks
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):